Cerulean Closes Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Cerulean Pharma (CERU) Announces Publication of Positive CRLX101 Data
April 13, 2015 7:14 AM UTCCerulean Pharma (Nasdaq: CERU) announced the publication of a manuscript in Breast Cancer Research and Treatment, describing preclinical data that demonstrate CRLX101, Ceruleans lead proprietary investigational drug, targets breast cancer stem cells and impedes resistance to anti-angiogenic therapy in breast cancer mouse models.
The results of the study demonstrate that CRLX101, a dual topoisomerase-1 and HIF-1 inhibitor, blocks the HIF-1 mediated increase in cancer stem cells induced by Avastin® (bevacizumab) in a triple-negative breast cancer xenograft... More
